...
首页> 外文期刊>Molecular and Cellular Endocrinology >An artificial thyroid hormone receptor mutant without DNA binding can have dominant negative effect.
【24h】

An artificial thyroid hormone receptor mutant without DNA binding can have dominant negative effect.

机译:没有DNA结合的人工甲状腺激素受体突变体可能具有显着的负面影响。

获取原文
获取原文并翻译 | 示例

摘要

The syndrome of resistance to thyroid hormone (RTH) encompasses a heterogeneous group of conditions which are caused by mutations of thyroid hormone receptor beta 1 (TR beta 1). Mutations usually cluster in two regions of the ligand-binding domain. The mutant receptors can inhibit normal receptor activity in a dominant negative manner, consistent with the dominant mode of inheritance of RTH. Recent evidence suggested that this dominant negative effect (DNE) of the RTH mutants involves competition for DNA binding and emphasized the essential role of intact DNA binding activity for mutants in order to exert DNE. However, we found that a Cys73Ser substitution in the DNA-binding domain (DBD) of wild-type produces a TR which can inhibit the transcriptional activation by TR alpha 1, either in the presence or absence of T3, on three different TRE-containing reporter genes, in transient co-transfection studies. Co-expression of TRv alpha 2, a TR alpha splicing variant, can enhance this DNE. However, DNE was not observed on the negatively-regulated TSH alpha Luc reporter gene when wild-type and DBD mutant were co-transfected at equimolar ratios. The DNE of DBD mutant is not reversed by co-transfection with excess retinoid X receptor alpha. DBD mutant alone can also inhibit the transactivation from a TK-luciferase reporter gene either linked with rat malic enzyme thyroid response element, or not. These observations parallel those we previously observed using TRv alpha 2. Our results indicate that a DBD mutant can have DNE, possibly through a mechanism similar to that of TRv alpha 2, which may involve interference with basal transcription factors. The clinical significance of these DBD mutants is currently unclear, but it is logical to expect such mutants do occur in nature.
机译:甲状腺激素抵抗综合征(RTH)涵盖了一组异质性疾病,这些疾病是由甲状腺激素受体beta 1(TR beta 1)的突变引起的。突变通常聚集在配体结合结构域的两个区域。突变受体可以以显性负性方式抑制正常受体活性,这与RTH的显性遗传方式一致。最近的证据表明,RTH突变体的这种显性负效应(DNE)涉及竞争DNA结合,并强调了完整的DNA结合活性对于突变体发挥DNE的重要作用。但是,我们发现野生型DNA结合结构域(DBD)中的Cys73Ser取代产生的TR可以抑制存在三个不同TRE的T3的存在或不存在时,TR alpha 1的转录激活。瞬时共转染研究中的报告基因。 TR alpha剪接变体TRv alpha 2的共表达可以增强DNE。但是,当野生型和DBD突变体以等摩尔比共转染时,在负调节的TSHαLuc报告基因上未观察到DNE。 DBD突变体的DNE不能通过与过量类视黄醇X受体α共转染而逆转。单独的DBD突变体也可以抑制来自TK-荧光素酶报道基因的反式激活,该基因与大鼠苹果酸酶甲状腺反应元件相连,也可以不相连。这些观察结果与我们之前使用TRv alpha 2观察到的结果相似。我们的结果表明,DBD突变体可能具有DNE,可能是通过类似于TRv alpha 2的机制引起的,该机制可能涉及对基础转录因子的干扰。目前尚不清楚这些DBD突变体的临床意义,但逻辑上期望此类突变体确实存在于自然界中是合乎逻辑的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号